Using Syva "EMIT" reagents and the Cobas Bio centrifugal analyzer, we have developed cost-effective assays for therapeutic drug monitoring of carbamazepine, phenobarbital, and phenytoin. With these optimized methods one can assay up to 2470 samples with a single 100-test EMIT kit with good precision and accuracy. Between-batch CVs, based on resuits of repeat analysis of routine patients' samples, were 4.6%, 7.0%, and 5.3%, respectively. Results correlated well with those by methods previously used [gas chromatography and fluorescence polarization (Abbott TDx)], but there was a negative bias (-10.9%) of our method for phenobarbital results in patients' samples, as compared with those obtamed with the TDx. and excretion and in their respouse to anti-epileptic drugs, and the therapeutic efficacy of the drugs correlates better with concentrations in plasma than with the dose. In addition to providing for individualization ofdrug therapy, monitoring drug concentrations in plasma is useful for detecting and discouraging noncompliance and helps to prevent unnecessary use of different drugs (1).
well with those obtained by other procedures, including GC and HPLC (2) (3) (4) (5) . However, the cost of consumables is higher than in the chromatographic methods, and a dil ferent immunoassay method is required for the measurement of each drug.
Various procedures have been described (6) (7) (8) for mothfying EMIT assays for use in the Cobas Bio centrifugal analyzer (Roche Products Ltd., Diagnostic Division, Welwyn Garden City, U.K.) to minimize reagent consumption and hence decrease the cost per sample. Here we describe the use of EMIT kits for carbamazepine, phenobarbital, and phenytoin modified for use with the Cobas Bio analyzer, along the lines ofthe cost-effective system devised by Sung and Neeley (8) for measurement of theophylline. We compared the results with those obtained by the methods we previously used in this laboratory (TDx for carbamazepine and phenobarbital; GC for phenytoin) and assessed the precision and reliability of the modified procedures. By using these cost-effective systems one can assay as many as 2470 samples with one 100-test EMIT kit.
Materials and Methods
TDx method. The Thx procedure was performed according to the manufacturer's instructions for carbamazepine and phenobarbital (1986 Assay Systems Manual).
GC method. Phenytoin
was extracted from acidified soi-urn or plasma into diethyl ether and measured by GC of the methylated derivative. Tolylphenylhydantoin was used as the internal standard. GC conditions were as follows: Sigma 3 instrument (Perkin-Elmer Ltd., Beaconsfield, U.K.) with nitrogen detector; column, 2% CDMS (cyclohexanedimethanol succinate) on Chromosorb W (1 m length); oven temperature, 220 #{176}C; injector and detector temperatore, 240 #{176}C; and carrier gas flow, 60 mL/min. EMIT reagents. EMIT kits containing reagents and calibratore were from Syva Co. Calibrators, controls, and stock "antibody/substrate" and "enzyme-labeled antigen" reagents were reconstituted and stored as recommended in the manufacturefs package insert. Stock "G6PINAD coenzyme" and "substrate booster" were prepared by adding 1.24 g ofglucose 6-phosphate (G6P) monosodium salt (cat. no. G-7879) and 2.91 g ofNAD (cat. no. N-7004; both from Sigma Chemical Co., Poole, Dorset, U.K.), to 10 mL of distilled water. This yielded 12 mL ofa solution containing, per liter, 366 mmol of G6P and 366 mmol of NAD , which we divided into five aliquots and stored at -20 #{176}C. The working buffer was prepared by diluting the stock buffer according to the manufacturer's instructions. Working antibody/substrate reagent was prepared by mixing stock reagent (1.5 mL), working buffer (103.5 mL), and stock G6P/NAD (2.1 mL). Working enzyme reagent was prepared by adding stock reagent (1.5 mL) to working buffer (9.0 mL). The manufacturer states that reconstituted kit reagents are stable for three months at 4#{176}C.
Cobas Bio procedures. Reagents, standards, tests, and controls were removed from the refrigerator and allowed to reach ambient temperature. Phenobarbital.
The within-batch precision was assessed 17 by using Seronorm controls (target value 95 jnnol/L), and 5.0 the between-batch precision was evaluated by using cali-10 bration standards and Seronorm controls. The mean CV 19 was 3.9%, significantly higher than that for the carbaxnaze-0 pine assay (2.1%). Evaluation of the between-batch preci-1 sion gave a mean CV of 9.0% (Table 3) (Table 4) .
The CV for the assay in routine use, based on repeat analysis of patients' samples, was 7.0%, compared with a mean value of 2.2% for the TDx method.
Results
The corresponding standardconcentrations [2] [3] [4] [5] [6] (anti-epileptic drug) controls can be expected to be within 10% of the value specified by Syva. The system was calibrated before each analytical run (current cost of calibration, about #{163}1.20, $2.03).
Controls. We used "Seronorm" (Nyegaard & Co., Oslo, Norway) control serum and EMIT-a.e.d. controls in assessing precision.
Carbamczzepine.
To assess the extent to which the calibration curve slope varies between analytical runs (with use of the same batch of working reagents), we examined curves for 22 runs. To negate the effect of between-assay "shifts," we subtracted the reaction rate for the zero calibrator from the reaction rate values for the standards. The results (Table 2) show that the slope of the curve is very constant.
However, the variation we observed was not entirely random: two of the lowest range values come from the same curve and all five ofthe highest from another one.
The precision of replicate measurements of carbamazepine was assessed by using Seronorm controls for withinbatch precision, and EMIT-a.e.d. controls, Seronorm controls, and repeat analysis of patients' samples for betweenbatch precision (Table 3) . Precision was good, the mean CVs being 4.5%. We assessed the accuracy ofthe modified 
Phenytoin.
Assessment of the within-batch precision based on 209 assays of a Seronorm control gave CVs in the range 1.7% to 5.7% with a mean of 3.4% (Table 3) . To evaluate between-batch precision, we used EMIT phenytoin controls, Seronorm controls, calibration standards, and repeat analysis of patients' samples. Mean CVs of 6.0% or less were obtained (Table 3) The precision of the assay, based on the use of repeat analysis controls in routine operation, gave a CV of5.3% as compared with 3.7% for the TDx method.
Discussion
Our modification of the EMIT system for use with the Cobas Bio analyzer has provided a method that is economical, rapid, and easy to perform, and is suitable for use outside of regular workshift hours. The between-batch CVs for the carbamazepine and phenytoin assays compared well with those for the TDx and GC methods we used previously. The precision of the Cobas Bio method for phenobarbital compares less well with the TDx method, and the Cobas Bio method shows a marked negative bias compared with the 2) . However, because ofwide interindividual variation in plasma concentrations required to achieve the desired anti-convulsant effect and the effects of tolerance on patients' responses to the drug, therapeutic drug monitoring for phenobarbital is of less value than for the other drugs studied, and the precision achieved with the Cobas Bio method for phenobarbital appears acceptable.
The costs per sample by the Cobas Bio methods (currently about 20 p, $0.34) are considerably less than by the TDx method (about #{163}3.10, $5.24). The Cobas Bio method is not less expensive than the GC method for phenytoin, but it is much quicker and much less labor-intensive. The Cobas Bio methods described here have been in use for 10 months for phenytoin, eight months for carbamazepine, and two months for phenobarbital, and have been found to be very reliable in routine operation.
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